secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001493152-25-011975
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack H1 net loss $11.6M; cash $9.6M; on track to implant first CBGM patients in Australia Q3 2025
--------------------------------------------------------------------------------

- Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.
- Cash and equivalents $9.6M as of June 30, 2025, expected to fund operations through 2025.
- Received ethical approval in Australia; first patient implants in multicenter feasibility study expected Q3 2025.
- Repurchased Series A warrants, eliminating warrant liability accounting and dilution overhang.
- Positive first-in-human CBGM data reported: MARD 7.7%, 99% data capture, no serious adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315225011975/0001493152-25-011975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315225011975/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer